Eli Lilly: CHMP recommends Jaypirca in leukemia
(CercleFinance.com) - Eli Lilly announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has issued a positive opinion for Jaypirca (pirtobrutinib) in the EU as a treatment for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) after treatment with a BTK inhibitor.
This opinion is based on the results of a Phase III trial showing a 46% reduction in the risk of progression or death compared with standard treatments, with a median progression-free survival of 14 months versus 8.7 months.
The company reports that Jaypirca has already received conditional approval for mantle cell lymphoma, and is awaiting a decision from the European Commission.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
This opinion is based on the results of a Phase III trial showing a 46% reduction in the risk of progression or death compared with standard treatments, with a median progression-free survival of 14 months versus 8.7 months.
The company reports that Jaypirca has already received conditional approval for mantle cell lymphoma, and is awaiting a decision from the European Commission.
Copyright (c) 2025 CercleFinance.com. All rights reserved.